Selection of recombinant MVA by rescue of the essential D4R gene
- Patricia S Ricci†1,
- Birgit Schäfer†1,
- Thomas R Kreil2,
- Falko G Falkner1 and
- Georg W Holzer1Email author
© Ricci et al; licensee BioMed Central Ltd. 2011
Received: 14 September 2011
Accepted: 12 December 2011
Published: 12 December 2011
Modified vaccinia virus Ankara (MVA) has become a promising vaccine vector due to its immunogenicity and its proven safety in humans. As a general approach for stringent and rapid selection of recombinant MVA, we assessed marker rescue of the essential viral D4R gene in an engineered deletion mutant that is fully replication defective in wild-type cells. Recombinant, replicating virus was obtained by re-introduction of the deleted viral gene as a dominant selection marker into the deletion mutant.
KeywordsRecombinant vaccines Uracil-DNA glycosylase Vaccinia virus Cell Line Transformed Defective viruses/genetics Defective viruses/growth & development
Modified vaccinia virus Ankara (MVA) was developed as a safer smallpox vaccine during the smallpox eradication campaign . For this purpose, vaccinia strain Ankara was passaged more than 500 times in primary chicken embryo fibroblast cells (CEF). Replication of MVA is almost completely restricted to avian cells, and the virus is strongly attenuated in vivo. The excellent safety record of this strain was established in vaccination campaigns in the 1970's, when over 120,000 humans including immune suppressed individuals were immunized [2, 3]. Safety of MVA as a smallpox vaccine has also been addressed by others in clinical studies [4–6].
The attenuated phenotype is the consequence of multiple changes in the viral genome. Six major deletions and numerous other mutations including small deletions, point mutations and insertions relative to the parental strain were mapped [7, 8]. MVA has been intensively studied as a vector for use in recombinant live vaccines . MVA-based live vaccines have already been under evaluation in numerous clinical trials, recently for instance for HIV [10, 11], influenza , and against smallpox . Safety was also demonstrated with a recombinant MVA-based cancer vaccine (TroVax) in clinical studies .
Recombinant MVA are usually generated by homologous recombination techniques [14, 15], followed by repeated rounds of plaque purification under selective conditions. Methods for clonal selection have been established previously for vaccinia virus in general, including dominant E. coli gpt marker selection  and lacZ color screening , and are equally used for work with MVA. Other techniques for the isolation of recombinant vaccinia virus (VV), such as tk- selection, cannot be applied to MVA due to its restriction to a few cell types. Specifically for MVA, certain host range selection methods have been developed that make use of the genetic basis of the growth restrictions of MVA. For example, introduction of the VV gene K1L as a marker which is naturally deleted in MVA, extends the host range to rabbit kidney cells . However, there might be regulatory concerns that selection markers can change the attenuated phenotype of MVA thereby impairing the well-established safety profile of MVA. For instance, the VV K1L gene encodes viral functions that impair important anti-viral defense mechanisms of the infected host. The K1L gene product suppresses activation of the transcription factor NF-κB . More recently, it was shown that K1L -alongside with C7L- is also involved in preventing RNA-activated protein kinase (PNK) -dependent and -independent shut-off of protein synthesis by the infected host . In MVA, the lack of a functional K1L gene enables early-phase PNK-mediated host responses possibly contributing to both the impairment of viral replication and the stimulation of the immune response .
Generally, plaque purification procedures are more difficult with MVA compared to replicating vaccinia strains, because MVA work is limited to a narrow range of cell substrates. Classically, MVA is grown and purified on primary CEF. Plaque formation on these cells is not as clear as with most permanent cell lines, and the work depends on cell supply of constant quality. To compensate for these shortcomings, additional detection methods such as immunostaining have been applied for MVA plaque isolation on CEF .
An elegant and stringent selection approach is the rescue of virus with wild-type (wt) -like growth properties by re-introduction of a previously deleted viral function. For MVA, deletion of the non-essential genes E3L and F13L, respectively [23, 24] resulted in viruses of altered plaque properties or narrowed host range, allowing the selection of recombinants after re-introduction of these genes and rescue of the wild-type phenotype.
While the latter selection methods are based on non-essential host range genes, we now attempted a rescue selection procedure by use of a parental MVA that lacks an essential function and that is entirely growth incompetent on wild-type cells. Deletion of the essential gene D4R from vaccinia virus and complementation of the deleted viral function by an engineered complementing cell line has been described earlier . The vaccinia virus gene D4R encodes the protein uracil DNA glycosylase, which catalyzes the removal of uracil residues from double-stranded DNA, and which is an indispensable component of the vaccinia DNA polymerase complex . Recently, knock-out of the D4R gene has been applied to MVA with the purpose of reduced vector antigen expression in recombinant vaccines . Growth of the knock-out virus requires a permanent cell-line that may be engineered to complement the viral function. For MVA which is largely restricted to avian cells, the avian cell line DF-1 was found to be appropriate for this task. The cell line DF-1 had been created after spontaneous immortalization of CEF and was initially investigated for the work with avian retroviruses . Because D4R-based dominant host range selection was found to provide a powerful selection method for replicating vaccinia recombinants , it was now attempted to adopt this technique also to MVA.
Materials and methods
Cell lines and viruses
The African green monkey cell line Vero (ATCC CCL-81), and the chicken embryo fibroblast cell line DF-1 (ATCC CCL-12203) were grown in DMEM (Biochrom) containing 5% of fetal calf serum (PAA), non-essential amino acids (NEAA) and Pen/Strep (Lonza). Primary chicken embryo cells (CEF) were isolated from 12 day old chicken embryos and grown in Med-199 (Gibco) containing 5% of fetal calf serum, Pen/Strep and NEAA.
Construction of the D4R defective vaccinia virus Lister (dVV-L) is described elsewhere . Modified vaccinia virus Ankara (Isolate MVA74 LVD6) was obtained from Dr. Bernard Moss, National Institute of Allergy and Infectious Diseases. This MVA isolate originates from three rounds of plaque purifications of MVA passage 572  and was frozen prior to the emergence of bovine spongiform encephalopathy. The virus rMVA-YF/d3 that carries the YFV prME cassette in the genomic del3 region is described elsewhere .
Retroviral transduction of DF-1 cells
The D4R gene was introduced into DF-1 cells by transduction with a retroviral vector that had been derived from the commercially available vector pLXSN, Invitrogen . Retroviral vector particles were generated in Vero cells by simultaneous transfection with the packaging plasmids pGAGPOL-gpt  and pALF (both kindly provided by W. Günzburg, University of Veterinary Medicine Vienna), and the vector plasmid pLXSN-D4R . The plasmids (7 μg each) were transfected into subconfluent Vero cells by calcium phosphate transfection as described before . After 2 days, the supernatant was collected, supplemented with 4 μg/ml polybrene and filtered through 0.45 μm filters (VWR). The retroviral vector containing supernatant was diluted 1:10 and used to infect DF-1 cells of passage 31. After 4 days, cells were split into medium containing 100 μg/ml G418 (Invitrogen). Media changes were made every 4 days until cell foci could be picked and expanded under continued selective pressure. In passage 38, a master cell bank of cDF-1 was frozen, of which one aliquot was thawed and expanded for a working cell bank. The working cell bank corresponds to passage 41 of the parental DF-1 line.
Construction of plasmids
The plasmid pDM-Zgpt contains the lacZ/gpt double marker cassette flanked by genomic sequences of MVA to drive homlogous recombination into the viral D4R locus. First, the MVA sequences, that flank the D4R gene at either side, were amplified by PCR, using MVA genomic DNA as the template. The left flanking region of the D4R gene was amplified using the forward primer 5'-CAT TGT TAA C TG TGA GCT ACT GTA GGT G-3' and the reverse primer 5'-CTC GAG GTC GAC AAG CTT CCA TGG TTA TAT CAA ATT AGA TAC C-3'. For cloning purposes, a HpaI restriction site (restriction sites underlined) was introduced into the forward primer. The reverse primer contained XhoI, SalI, HindIII and NcoI as a future multiple cloning site. The MVA D4R right flank was generated by PCR with the forward primer 5'-GTC GAC CTC GAG GGC GCC GCG GCC GC T GCT TTA GTG AAA TTT TAA C-3' containing the restriction sites SalI, XhoI, EheI, NotI, and the reverse primer 5'-CGT AAG CGG AAG AGC ACT ATT GTT GTT CAT ATC CAC G-3'. The PCR products were sequentially cloned into pPCR-ScriptAmpSK(+) (Stratagene). In the resulting construct pDM, the MVA D4R flanks (left flank: 836 bp; right flank: 685 bp) frame a multiple cloning site. Next, the lacZ/gpt double marker cassette from pDW-2  was cloned via HindIII/SalI restriction into pDM to generate pDM-Zgpt.
The MVA D4R gene was amplified by PCR from MVA genomic DNA with the forward primer 5'-AGG CGT TTG TAT TCG CTT GG-3', and the reverse primer 5'-ACA CCA TGG GCT AGC TCG CGA TTA ATA AAT AAA CCC TTG AGC C-3'. The forward primer binds to the genomic MVA DNA upstream of an Eco105I site that is located 27 bp outside of the the D4R gene. The reverse primer contained the restriction sites NcoI, NheI and NruI for a MCS downstream of the D4R gene. Using the restriction sites Eco105I and NcoI, the PCR product was cloned into pDM resulting in pDM-D4R.
To construct the plasmid for integration of the YFV prME into the D4R/D5R locus, the yellow fever prME gene cassette was excised from plasmid pd3-YFprMEco and cloned into pDM-D4R, using the restriction sites NheI and SalI. The resulting plasmid pDM-D4R-YF contains the YFV prME expression cassette downstream of the D4R gene .
Generation of viruses
Recombinant virus was generated by homologous recombination . Confluent monolayers of the indicated cell types were infected/transfected according to the procedures essentially described before .
Infection/transfection with MVA-wt and the plasmid pDM-Zgpt was done in CEF. Recombinant MVA was selected by seven rounds of plaque purification with gpt selection  and lacZ screening  in the D4R complementing cell line cDF-1. A plaque isolate that did not show any growth on wt DF-1 cells was expanded in cDF-1 and a purified virus stock was prepared as previously described . The resulting defective MVA was termed dMVA-ZG.
Wild type DF-1 cells were infected with dMVA-ZG, and the plasmid pDM-D4R-YF was used for transfection. Plaque purification and amplification were carried out in wild type DF-1 cells.
Characterization of defective MVA by PCR
PCR was performed to confirm the expected genomic structure of the defective virus dMVA-ZG and to test for contamination with residual wild-type MVA. For this purpose, sucrose cushion purified dMVA-ZG stock was used. For spike controls, 1%, 0.1%, 0.01% and 0.001% MVA-wt were added to dMVA-ZG samples. After digestion with 0.5 μg/μl proteinase K (Sigma) for 3 hrs at 56°C and 2 hrs at 95°C, 1 μl samples corresponding to 1 × 105 pfu were subjected to PCR.
The reaction was carried out with the primers 5'-ACC TTC CAA CTG TGG ATA CTC TG-3' and 5'-TCG AAT GAA ATA AAC CCT GGT-3' resulting in a PCR signal of 2430 bp with MVA-wt, and of 5624 bp with dMVA-ZG as a template.
Growth experiments with MVA and vaccinia virus
Confluent cells cultivated in 6-well plates were infected with 5 × 104 tissue culture infectious doses 50% (TCID50) of the respective MVA or vaccinia virus, followed by media change after 1 h. Cells were kept in a CO2 incubator at 37°C. At the respective time points post infection, cells were scraped into the medium and disrupted by three cycles of freeze/thaw and ultrasonication. The virus titer was determined by TCID50 assay, and the output/input ratio was calculated. MVA was grown and titrated on the cell line DF-1, and dMVA-ZG on the complementing cell line cDF-1.
Determination of infectious titers
Infectious titers were assayed by TCID50 assay. Serial ten-fold dilutions of specimen were applied to CEF in 96-well plates, and virus induced cytopathic effect was evaluated by light microscopy after 5-7 days of incubation at 37°C in a CO2 atmosphere. Viral titers were calculated according to the formula of Spearman and Kaerber  and were expressed as TCID50/ml. One TCID50/ml corresponds to about 0.5 plaque forming unit (pfu), as determined in a series of parallel measurements.
Plaques of MVA that express YFV prME antigen were identified by double immunostaining.
cDF-1 cells were infected with recombinant YF prME-expressing MVA for a period of 4 days, and were then fixed with methanol/acetone (1:1). To detect plaques of YFV prME expressers, a guinea pig antiserum against YFV-17D (Lot # 070824/T4, Baxter) was used. Goat anti-guinea pig horseradish peroxidase-conjugated IgG (Jackson ImmunoResearch Laboratories, Inc.) was used as a secondary antibody. Plaques were visualized with diaminobenzidine (DAB) solutions including nickel (Vector Laboratories), resulting in black plaques. In a subsequent round, plaques were additionally stained for vaccinia antigens, using a polyclonal rabbit anti-vaccinia virus serum (Lot no. VVSKP26012006, Baxter). In this case, the secondary antibody was a goat anti-rabbit peroxidase-conjugated IgG (Jackson Inc), and staining was done with DAB solution without nickel, resulting in brown plaques, essentially as described earlier .
Growth assay of defective MVA for replicating contaminants
To detect replication competent virus in defective virus stocks, ten 175 cm2 cell culture flasks of confluent DF-1 cells were infected with a total of 2 × 106 pfu (moi = 0.05) of dMVA-ZG. In parallel cell culture flasks were infected with 100 pfu wild-type MVA or with a mixture of 2 × 106 pfu dMVA-ZG and 100 pfu wild-type MVA to control the sensitivity of detection. Uninfected DF-1 cells served as a negative control. Five days post infection plaques of residual replication competent virus were visualized by crystal violet staining.
Whole cell lysates were prepared from 5 × 106 infected cells by three cycles of freezing/thawing, followed by ultrasonication and denaturation in protein loading buffer (Fermentas). Aliquots corresponding to 1 × 105 cells were resolved by 12% polyacrylamide gel electrophoresis. Blotting was performed essentially as described previously . For detection, a polyclonal guinea pig antiserum (Lot # 070824/T4, Baxter) against YFV-17D, and anti-guinea pig alkaline phosphatase-conjugated immunoglobulin (Sigma) as the second antibody, were used.
Isolation of genomic DNA and real-time PCR
Recombinant virus plaques were picked and suspended in 500 μl DMEM, and used to infect cDF-1 cells in 6-well plates to amplify the recombinant virus and potential residual parental dMVA in the stocks. As controls, cells were infected in parallel with the parental dMVA-ZG, wild-type MVA and rMVA-YF/del3. After 5 days, infected cells were harvested, and genomic DNA was isolated using DNeasy kit (Quiagen Inc.). Aliquots corresponding to 0.4% of the 1 ml harvest from a 6-well were used as template in quantitative PCR reactions. Real-time PCR was performed with 2 μl of genomic template DNA in a total volume of 20 μl using Taqman gene expression master mix (Applied BioSystem), and primers and probes at a final concentration of 900 nM and 200 nM, respectively, using a StepOnePlus real time PCR system (ABI, 4376598).
For amplification of the individual genomic targets, the following primer-probe sets were used:
YFV prME-specific: FWD (5'-TGA TGC AGG TCA AAG TGT CTA AGG-3'), RWD (5'-TGT TGA TGG CGG CTG TCA-3'); and Probe (5'-6FAM-CTG CCG GAT CCC CGT-MGB-3').
LacZ-specific: FWD (5'-ATT CAG GCT GCG CAA CTG TT-3'), RWD (5'-CAG CAC ATC CCC CTT TCG-3'), and Probe (5'-6FAMAAG GGC GAT CGG TGC G-MGB-3').
MVA 173R gene-specific: FWD (5'-GCA ACG GCG AAA CAA AAT ATT T-3'), RWD (5'-ATT AGG ACA CGT AAC AGT ATC ATT CCA-3'), and Probe (5'-6FAM-TTG CGA AGA AAA AAA TGG AA-MGB-3').
Specific for plasmid DNA (Ampr gene): FWD (5'-CCA ACG ATC AAG GCG AGT TAC-3'), qPCRVVamp-RWD (5'-CCG AAG GAG CTA ACC GCT TT-3'), and Probe (5'-6FAM-TGA TCC CCC ATG TTG TG-MGB-3').
To generate standard curves for determination of genomic equivalents, plasmids containing Ampr -, lacZ and 173R sequences and a plasmid containing the YFV prME gene, were used in ten-fold dilutions ranging from 1 × 108 to 1 × 103 DNA copies.
Results and discussion
Generation of the D4R complementing cell line cDF-1
Traditionally, MVA is propagated in primary CEF. In order to propagate the D4R-deleted MVA that should serve as the parental strain for the intended selection procedure, a stably D4R-expressing cell line was required. Ideally, the cell line should be non-tumorigenic and of avian origin to allow the growth of MVA. For technical reasons, formation of clear MVA plaques is a desirable general characteristic of the cell line of choice. To evaluate the cell line DF-1 for the intended selection of recombinant replicating MVA, we assessed it for propagation of MVA using primary CEF as a reference. In DF-1, a maximal MVA titer (about 7.4 log10 TCID50) was reached as early as day 1. In plaque assays, MVA formed confined, circular plaques on DF-1 cells, making this cell line useful for the intended plaque purification of defective MVA.
The D4R complementing DF-1 based cell line was generated by retroviral transduction analogous to a Vero-based complementing cell line described previously . We used the D4R-defective vaccinia virus Lister dVV-L  to screen for the cell clone that complemented most efficiently the lacking viral function. The DF-1 cell clone #4A allowed amplification of the defective vaccinia virus to the highest titers (data not shown), and was therefore further expanded to obtain the cell line cDF-1.
Generation of a non-replicating parental virus
The defective virus dMVA-ZG is free of MVA-wt
The absence of replicating contaminants from the dMVA-ZG stock was of special interest because the reconstitution of growth should serve as the key selection criterion for further recombinants in the dominant host range selection procedure. To phenotypically verify the absence of replicating MVA, a growth assay on DF-1 was performed that was capable to detect 1 pfu replicating MVA in 2 × 107 pfu of dMVA-ZG. No plaques were detectable after a 5 days incubation further demonstrating the purity of the preparation.
Generation of recombinant MVA by rescue of the D4R gene
For the generation of MVA recombinants with restored replication, we constructed the basic recombination plasmid pDM-D4R. This plasmid contains the D4R gene in its natural genomic context, with an additional multiple cloning site (MCS) for the insertion of genes of interest between the D4R and the D5R gene. Introduction of foreign genes into the D4R/D5R intergenic region was described earlier for recombinant vaccinia virus . The genomic sequence adjacent to the D4R gene is highly conserved among vaccinia strains, suggesting that also in MVA, insertions in the D4R/D5R locus should not significantly interfere with virus viability. As proof of concept, we constructed the plasmid pDM-D4R-YF (Figure 1b) by placing an expression cassette for the yellow fever virus (YFV) surface proteins (prME) into the MCS of the basic recombination vector. Using this recombination plasmid together with the defective parental virus dMVA-ZG, we attempted the generation of a replication competent, YFV antigen-expressing MVA, termed rMVA-YF/D4. The design of the expression cassette containing the YFV prME sequence is described elsewhere .
Infection/transfection for homologous recombination between the defective MVA and the recombination plasmid pDM-D4R-YF and all subsequent steps were performed in the wt DF-1 cell line. Virus was harvested 2 days later and plated onto fresh cells under agarose overlay in the absence of selective agents. After 3 days, neutral red and X-Gal staining revealed clearly visible plaques of wild-type size. In this first round of plaque purification, already 70% of the plaques were no longer stainable by X-Gal, indicating the absence of parental β-galactosidase (β-Gal)-expressing dMVA-ZG virus. Twelve white plaques were randomly picked from this first round of plating, and were checked for absence of parental virus. Using cDF-1 cells that support the growth of both the parental dMVA-ZG and the D4R-restored rMVA-YF/D4 the isolates were first expanded in order to obtain sufficient material for quantitative tests. For phenotypic analysis, the isolates were subjected to plaque assay on cDF-1 cells. When plaques were stained with X-Gal to detect parental dMVA-ZG in the plaque assay, all 12 isolates were phenotypically free from β-Gal positive parental virus at a test sensitivity of approximately 1 parental virus among 50 plaques.
Real-time PCR quantification of different target sequences in virus isolates obtained by the marker rescue procedure
The presence of the gene of interest was measured by a YFV prME gene specific PCR reaction, where 8.14-8.55 GE/ml (mean 8.38) were found, consistent with the total MVA DNA quantification. Expectedly, only background signals (max. 3.57 log GE/ml) were obtained with the controls wild-type MVA and dMVA-ZG that did not contain any YFV sequences.
Two PCRs were performed specifically to detect intermediate structures in the recombinant samples. In the first analysis that targeted lacZ sequences from the parental virus dMVA-ZG, the isolates rMVA-YF/D4 ranged from 3.17 to 3.66 GE/ml which is equivalent to the background (3.58 log GE/ml) measured in uninfected DF-1 cells. A second analysis targeted the ampicillin resistance gene to detect intermediate viral genomes that form during recombination and that still contain the complete plasmid backbone. Also in this analysis, the isolates gave results at the background level of the controls, suggesting that residual intermediate structures were practically absent in the isolates.
The MVA intergenic D4R/D5R insertion locus
Expression of a gene of interest without clonal selection
The YFV envelope protein was detectable as a 50 kDa band already after one virus passage (lane 3). After two passages (lane 4), expression was similar to the control rMVA-YF/del3 that had been purified by conventional clonal selection (lane 8). When the same procedure was done with a control plasmid that contained the YFV prME cassette but not the D4R gene as a selectable marker, E protein expression was undetectable at all passages (lanes 6, 7). This indicated that the transgene expression from the transfected plasmid DNA itself was neglectable, and that the YFV E protein detected by Western blotting reflected replicating recombinant MVA virus.
In order to investigate the proportion of recombinant virus into more detail, the virus from the different passages was subjected to plaque assay on cDF-1 cells that equally support growth of the replicating, i.e. recombinant and the defective parental MVA. Plaques were immune-stained with antisera directed either to yellow fever virus prME antigen or to vaccinia virus, thereby discriminating recombinant prME-expressing plaques from non-expressing MVA plaques.
Percentage of transgene expressing virus plaques after passages without clonal selection
prME Positive Plaques (%)
Primary crude stock
46.3 ± 1.331
92.1 ± 0.231
98.1 ± 0.781
97.1 ± 2.861
This study describes a method to create recombinant MVA vectors, based on the principle of dominant host range selection upon rescue of the viral D4R gene . The presented approach allows for rapid isolation of the target recombinant, resulting in parental virus-free recombinant stocks in a single round of plaque purification. While generation of recombinants of the highly attenuated MVA is traditionally more difficult than of fully replicating vaccinia viruses, the D4R-dominant host range selection represents a simple and stringent alternative to integrate genes of interest into MVA. Traditional selection methods frequently involve the introduction of foreign selection marker genes, which may be undesired for the use in live vaccines. Marker genes may be de-stabilized by flanking tandem DNA repeats [18, 41], which however demands for additional plaque purifications to select for the marker-free genotype. As an alternative to the homologous recombination method to generate recombinant vaccinia virus, the cloning and manipulation of the entire vaccinia genome in a bacterial artificial chromosome (BAC) has been described . Recently, this method was also applied to MVA, and was proposed as a rapid approach for the generation of recombinant MVA [43, 44]. While the BAC technology offers the advantage of targeting any genomic locus of MVA, the method is dependent on the use of a helper virus, and results in recombinants that carry the complete BAC plasmid backbone in addition to the gene of interest. The BAC construct can also be designed to favour its excision by spontaneous homologous recombination , requiring however for additional plaque purifications or serial passage similar to the previously described marker destabilization. In contrast, the dominant host range selection procedure directly results in recombinant viruses without any foreign marker sequences by re-introduction of the essential viral D4R gene as the selection marker.
As a complementing cell line for the defective MVA, we generated a D4R-expressing avian DF-1 cell line, because of the advantageous properties of these cells with respect to virus propagation and plaque formation. Our approach of engineering the D4R gene into the cells by retroviral transduction has been applied previously to a simian cell line , and now successfully to an avian cell line, suggesting that this strategy is applicable to further cell lines that may be considered for propagation of MVA. In the present approach, the complementing DF-1 cell line supported growth of the defective MVA to levels similar to the wt virus. A D4R complementing DF-1 cell line by Garber and colleagues  who used a different technique resulted in similar defective MVA titers, i.e. approximately 5 × 107 pfu/ml at 24 hrs post infection. For use in the dominant selection procedure, the absolute titer of the defective virus is not critical. However, the growth kinetics of dMVA suggest that the expression level of the vaccinia uracil DNA glycosylase by the cell line cDF-1 was not limiting for viral replication, hence providing full complementation of the defective virus.
The approach of selecting recombinant virus by reconstitution of the viral D4R gene allowed isolation of clonal recombinant virus in a single round of plaque purification. The parental defective MVA contains a lacZ marker cassette that supports screening of descendant recombinant virus. In the initial plating, about 30% of the plaques appeared blue, indicating that they still contained parental virus. However, by picking white plaques, all of the 12 isolates were found to be already pure recombinants without intermediate structures as analyzed by quantitative PCR.
Because of the constant selection pressure against the parental defective virus, it is feasible to obtain and amplify recombinant virus stocks directly after infection/transfection without any further purification steps. This simplified method is no option for the production of well-defined virus stocks, but it represents a powerful tool e.g. if rapid and efficient transgene expression for analytical purposes is desired. As an example, we generated a recombinant virus stock without any plaque purification, achieving 98% purity in only two blind passages. The low amount of residual non-expressing virus suggests that this method is also useful if quantitative assessment of expression levels, e.g. to perform promoter studies. Principally, this type of enrichment procedure is feasible with any stringent selection marker. This has been demonstrated previously with the MVA F13L gene as a selectable plaque size marker , where close to 100% recombinant virus was achieved after 5 blind passages. However, enrichment procedures that make use of non-essential genes such as F13L provide a less stringent selection pressure, because the parental virus is still replicating, though at a reduced growth rate. On the other hand, deletion of non-essential host range genes such as K1L provides selective conditions in certain cell systems , but growth restriction of the parental virus is not maintained once the recombinant virus stock is transferred to avian cells-the normal substrate for MVA. While recombinant stocks obtained in this way are bound to be overgrown by parental virus under standard culture conditions, the defect in D4R-deleted MVA provides constant selective pressure in favor of the D4R bearing recombinant virus in any natural host.
The D4R dominant host range selection represents a quick and stringent method to generate recombinant MVA viruses. The method represents an alternative to current selection techniques that rely on additional marker genes, chemical agents, and multiple rounds of plaque purification. In contrast to traditional homologous recombination protocols and to the recently described BAC cloning procedure, the less laborious D4R-dominant host range selection approach by principle does not require foreign marker genes, resulting in MVA recombinants that are free from marker gene sequences and that thus meet the state-of-the-art requirements for use as live vaccines.
Modified vaccinia virus Ankara
Chicken embryo fibroblast cells
RNA-activated protein kinase
Non-essential amino acids
Yellow fever virus
Precurser protein of the matrix and envelope proteins
Tissue culture infectious dose 50%
Plaque forming unit
Multiple cloning site
E. coli β-Galactosidase
MVA genomic deletion III locus.
We would like to thank Marie-Luise Zips for carrying out the DNA sequencing.
- Mayr A, Hochstein-Mintzel V, Stickl H: Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 1975, 3: 6-14. 10.1007/BF01641272View ArticleGoogle Scholar
- Mayr A, Stickl H, Muller HK, Danner K, Singer H: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol B 1978, 167: 375-390.PubMedGoogle Scholar
- Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A: MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 1974, 99: 2386-2392. 10.1055/s-0028-1108143View ArticlePubMedGoogle Scholar
- Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS: Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007, 25: 1513-1525. 10.1016/j.vaccine.2006.10.047PubMed CentralView ArticlePubMedGoogle Scholar
- von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P: A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010, 28: 1209-1216. 10.1016/j.vaccine.2009.11.030PubMed CentralView ArticlePubMedGoogle Scholar
- Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R: Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010, 201: 1361-1370. 10.1086/651561PubMed CentralView ArticlePubMedGoogle Scholar
- Antoine G, Scheiflinger F, Dorner F, Falkner FG: The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244: 365-396. 10.1006/viro.1998.9123View ArticlePubMedGoogle Scholar
- Meyer H, Sutter G, Mayr A: Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991,72(Pt 5):1031-1038.View ArticlePubMedGoogle Scholar
- Drexler I, Staib C, Sutter G: Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004, 15: 506-512. 10.1016/j.copbio.2004.09.001View ArticlePubMedGoogle Scholar
- Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L: A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011, 29: 1948-1958. 10.1016/j.vaccine.2010.12.104PubMed CentralView ArticlePubMedGoogle Scholar
- Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA: Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010, 5: e13983. 10.1371/journal.pone.0013983PubMed CentralView ArticlePubMedGoogle Scholar
- Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC: Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52: 1-7. 10.1093/cid/ciq015PubMed CentralView ArticlePubMedGoogle Scholar
- Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de BJ, Goonewardena M, Naylor S, Harrop R: Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010, 16: 5539-5547. 10.1158/1078-0432.CCR-10-2082View ArticlePubMedGoogle Scholar
- Mackett M, Smith GL, Moss B: Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982, 79: 7415-7419. 10.1073/pnas.79.23.7415PubMed CentralView ArticlePubMedGoogle Scholar
- Panicali D, Paoletti E: Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982, 79: 4927-4931. 10.1073/pnas.79.16.4927PubMed CentralView ArticlePubMedGoogle Scholar
- Falkner FG, Moss B: Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 1988, 62: 1849-1854.PubMed CentralPubMedGoogle Scholar
- Chakrabarti S, Brechling K, Moss B: Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 1985, 5: 3403-3409.PubMed CentralView ArticlePubMedGoogle Scholar
- Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G: Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 2000, 28: 1137-6-1148.PubMedGoogle Scholar
- Shisler JL, Jin XL: The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol 2004, 78: 3553-3560. 10.1128/JVI.78.7.3553-3560.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Backes S, Sperling KM, Zwilling J, Gasteiger G, Ludwig H, Kremmer E, Schwantes A, Staib C, Sutter G: Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha. J Gen Virol 2010, 91: 470-482. 10.1099/vir.0.015347-0View ArticlePubMedGoogle Scholar
- Lynch HE, Ray CA, Oie KL, Pollara JJ, Petty IT, Sadler AJ, Williams BR, Pickup DJ: Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication. Virology 2009, 391: 177-186. 10.1016/j.virol.2009.06.012PubMed CentralView ArticlePubMedGoogle Scholar
- Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B: A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12: 1032-1040. 10.1016/0264-410X(94)90341-7View ArticlePubMedGoogle Scholar
- Hornemann S, Harlin O, Staib C, Kisling S, Erfle V, Kaspers B, Hacker G, Sutter G: Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol 2003, 77: 8394-8407. 10.1128/JVI.77.15.8394-8407.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Sanchez-Puig JM, Blasco R: Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker. Biotechniques 2005, 39: 665-670. 10.2144/000112012View ArticlePubMedGoogle Scholar
- Holzer GW, Falkner FG: Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. J Virol 1997, 71: 4997-5002.PubMed CentralPubMedGoogle Scholar
- De Silva FS, Moss B: Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured cells. J Virol 2003, 77: 159-166. 10.1128/JVI.77.1.159-166.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB: Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 2009, 4: e5445. 10.1371/journal.pone.0005445PubMed CentralView ArticlePubMedGoogle Scholar
- Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK: The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 1998, 248: 295-304. 10.1006/viro.1998.9290View ArticlePubMedGoogle Scholar
- Holzer GW, Gritschenberger W, Mayrhofer JA, Wieser V, Dorner F, Falkner FG: Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 1998, 249: 160-166. 10.1006/viro.1998.9307View ArticlePubMedGoogle Scholar
- Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG: Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 2002, 76: 7713-7723. 10.1128/JVI.76.15.7713-7723.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Schaefer B, Holzer GW, Joachimsthaler A, Coulibaly S, Schwendinger M, Crowe BA, Kreil TR, Noel PN, Falkner FG: Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One 2011, 6: e24505. 10.1371/journal.pone.0024505View ArticleGoogle Scholar
- Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 1989, 7: 980-989.PubMed CentralPubMedGoogle Scholar
- Markowitz D, Goff S, Bank A: A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988, 62: 1120-1124.PubMed CentralPubMedGoogle Scholar
- Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Bruhl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG: Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol 2009, 83: 5192-5203. 10.1128/JVI.02081-08PubMed CentralView ArticlePubMedGoogle Scholar
- Graham FL, van der Eb AJ: A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973, 52: 456-467. 10.1016/0042-6822(73)90341-3View ArticlePubMedGoogle Scholar
- Joklik WK: The purification fo four strains of poxvirus. Virology 1962, 18: 9-18. 10.1016/0042-6822(62)90172-1View ArticlePubMedGoogle Scholar
- Finney DJ: Statistical methods in biological assay. 1st edition. London: Griffin; 1952.Google Scholar
- Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW: Preparation of cell cultures and vaccinia virus stocks. In Current Protocols in Molecular Biology. John Wiley & Sons Inc.; 1998:16.16.1-16.16.13.Google Scholar
- Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76: 4350-4354. 10.1073/pnas.76.9.4350PubMed CentralView ArticlePubMedGoogle Scholar
- Antoine G, Scheiflinger F, Holzer G, Langmann T, Falkner FG, Dorner F: Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes. Gene 1996, 177: 43-46. 10.1016/0378-1119(96)00267-3View ArticlePubMedGoogle Scholar
- Scheiflinger F, Dorner F, Falkner FG: Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol 1998, 143: 467-474. 10.1007/s007050050303View ArticlePubMedGoogle Scholar
- Domi A, Moss B: Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci USA 2002, 99: 12415-12420. 10.1073/pnas.192420599PubMed CentralView ArticlePubMedGoogle Scholar
- Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC: Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 2008, 3: e1638. 10.1371/journal.pone.0001638PubMed CentralView ArticlePubMedGoogle Scholar
- Cottingham MG, Gilbert SC: Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. J Virol Methods 2010, 168: 233-236. 10.1016/j.jviromet.2010.04.012View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.